Not Yet Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm
NCT07431216
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression
Sponsor: Lantern Pharma Inc.
Conditions
Histopathology Confirmed Supratentorial GBM at First Recurrence IDHm Grade 4 Astrocytoma IDHwt GBM
Interventions
STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle. Spironolactone (drug)
Updated 1 time since 2026 Last updated: Feb 18, 2026 Started: Apr 1, 2026 Primary completion: Feb 1, 2027 Completion: May 1, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1/PHASE2 trial investigates Histopathology Confirmed Supratentorial GBM at First Recurrence and IDHm Grade 4 Astrocytoma and is currently actively recruiting participants. Lantern Pharma Inc. leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Lantern Pharma Inc.
- Starlight Therapeutics Inc.
Data source: Lantern Pharma Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.